Rohto Pharmaceutical

Diversified pharma/consumer health, regenerative-medicine cell therapy

4527 · TSE · Japan

Public Market Listing

4527TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Rohto Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Cardiac cell therapyCell therapy
Heart Failure

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
ADR-002KPhase 2Ischemic Heart Disease
Est. primary completion 2028-09-30 · NCT07192211 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$1.1B———report ↗

Rohto Pharmaceutical reported revenue of $1,125.51M for H1 2026.

Figures only: this period's report disclosed no narrative text

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$2.3B$91M$522M—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.0B$98M$488M—report ↗
2024-FY$1.9B$92M$572M—report ↗
2023-FY$1.8B$81M$583M—report ↗